FINANCE REPORT OF EMCURE

A multinational pharmaceutical company headquartered in Pune, Maharashtra, Emcure

Pharmaceuticals Limited operates in the pharmaceutical business. Products offered by Emcure
include tablets, capsules (both soft gel capsules and hard-gel capsules) and injectables.

BOARD OF DIREDTORS:

Director Name Designation Appointment Date

HITESH SOHANLAL JAIN Director 27 July 2021

VIDYA RAJIV YERAVDEKAR Additional Director 16 April 2021

SAMONNOI SAJANI BANERJEE Director 20 May 2014

NAMITA VIKAS THAPAR Wholetime Director 28 July 2014

VIJAY KESHAV GOKHALE Additional Director 16 April 2021

PALAMADAI SUNDARARAJAN JAYAKUMAR Director 22 July 2020

SUNIL RAJANIKANT MEHTA Wholetime Director 05 June 2013

SATISH RAMANLAL MEHTA Managing Director 16 April 1981

BERJIS MINOO DESAI Director 03 April 1997

SHAILESH KRIPALU AYYANGAR Director 16 April 2021

SHREEKANT KRUSHNAJI BAPAT Director 26 June 1999

VISION:

To provide quality healthcare solutions globally by leveraging our scientific strengths.

CORE VALUES:

We are guided by our core values of quality & patient-focused, integrity, innovation, teamwork &
respect.

• Quality & patient focused

• Integrity
• Innovation
• Team work & Respect
• Value Driven

MILESTONE:

• 2021

mRNA vaccine enters trials

• 2019

Sanand Injectables facility commenced USFDA approval of Sanand and F-II (API).

TENECTASE approved as emergency care for stroke

• 2017

Set up facility at Sikkim/Bangalore

• 2016

Acquired Bharadwaj Pharma GMBH in Germany

• 2015

Acquired Marcan Pharmaceuticals Inc., Canada

• 2014

Acquired Tillomed Laboratories, United Kingdom.

Bain capital acquired Blackstone’s stake in Emcure

• 2012

Worldwide rights of BICNU acquired.

Commenced EU operations with formation of Emcure UK

• 2010

Cytotoxic facility commenced in Hinjewadi

• 2009

Solid Dosage facility commenced in Jammu

 AWARDS & RECOGNITION

Marketing - 2021

• Exafib - CIMS Medica Healthcare Excellence Award 2021 – Emerging Brand of the Year
(Cardiac Care)
• KNOW THROMBOSIS - CIMS Medica Healthcare Excellence Award 2021 – Most Engaging
Scientific Platform from Pharma Company
• Pronto Consult Consumer Award –Golden Impact Award Ferium 500 Injection

Manufacturing- 2018-19

BEST API PATENTS AWARD 2018-19 (Highest Number of API patents) by Indian Drug
Manufacturers Association

HR & Corporate

• DBT-Biotech Award – Dr.Sanjay Singh for Process Development and Commercialization

award 2019 for the development of Tenectase, a 3rd generation thrombolytic
glycoprotein for acute ischemic stroke (AIS)
• National Safety Council – Maharashtra Safety Award – 2019 for Zero Accident
• DISH-Narayan Meghaji Lokhande Health & Safety Award 2019 – Industrial Best Practices

FINANCIAL STATEMNT

Profit & loss statement

BALANCE SHEET: click here

FINANCIAL RATIOS:

Operating Revenue Over INR 500 cr

EBITDA 75.57 %

Networth 20.23 %

Debt/Equity Ratio 0.57

Return on Equity 18.27 %

Total Assets 25.62 %

Fixed Assets -1.99 %

Current Assets 20.34 %

Current Liabilities 29.67 %

Trade Receivables -12.20 %

Trade Payables 30.93 %

Current Ratio 1.24